NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
19.87
Dollar change
+0.07
Percentage change
0.35
%
Index- P/E- EPS (ttm)-7.31 Insider Own43.39% Shs Outstand18.67M Perf Week5.97%
Market Cap371.02M Forward P/E- EPS next Y-4.71 Insider Trans13.06% Shs Float10.57M Perf Month-11.29%
Enterprise Value67.40M PEG- EPS next Q-0.97 Inst Own55.48% Short Float12.69% Perf Quarter6.54%
Income-58.67M P/S- EPS this Y40.05% Inst Trans48.36% Short Ratio6.13 Perf Half Y-60.70%
Sales0.00M P/B1.23 EPS next Y-15.14% ROA-28.82% Short Interest1.34M Perf YTD-56.96%
Book/sh16.12 P/C1.21 EPS next 5Y5.91% ROE-30.10% 52W High61.07 -67.46% Perf Year24.73%
Cash/sh16.40 P/FCF- EPS past 3/5Y41.06% 26.54% ROIC-19.47% 52W Low13.70 45.04% Perf 3Y63.94%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.17% 6.54% Perf 5Y-91.92%
Dividend TTM- EV/Sales- EPS Y/Y TTM-187.53% Oper. Margin- ATR (14)1.44 Perf 10Y-
Dividend Ex-Date- Quick Ratio22.92 Sales Y/Y TTM- Profit Margin- RSI (14)43.26 Recom1.14
Dividend Gr. 3/5Y- - Current Ratio22.92 EPS Q/Q49.17% SMA20-8.14% Beta1.46 Target Price82.33
Payout- Debt/Eq0.01 Sales Q/Q- SMA50-5.98% Rel Volume0.51 Prev Close19.80
Employees51 LT Debt/Eq0.00 EarningsMay 08 AMC SMA200-36.23% Avg Volume218.72K Price19.87
IPOJun 21, 2018 Option/ShortYes / Yes EPS/Sales Surpr.14.36% - Trades Volume113,343 Change0.35%
Date Action Analyst Rating Change Price Target Change
Jun-11-25Resumed Raymond James Outperform $76
Apr-21-25Initiated Mizuho Outperform $51
Nov-20-24Initiated Raymond James Outperform $65
Aug-22-24Initiated Wells Fargo Overweight $55
Jun-26-24Initiated Piper Sandler Overweight
Jun-24-24Initiated TD Cowen Buy
Dec-18-23Downgrade Mizuho Buy → Neutral
Jan-05-22Downgrade BTIG Research Buy → Neutral
Nov-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $24 → $7
Jun-15-21Initiated BTIG Research Buy $23
Jun-30-25 08:00AM
Jun-24-25 05:42PM
May-17-25 10:40AM
May-13-25 09:55AM
May-08-25 04:01PM
08:00AM Loading…
May-07-25 08:00AM
May-01-25 05:59AM
Apr-23-25 05:51AM
Apr-15-25 08:00AM
Mar-20-25 04:01PM
Mar-04-25 08:26PM
Feb-20-25 08:00AM
Feb-03-25 06:30AM
Jan-30-25 06:30AM
Dec-03-24 04:01PM
04:01PM Loading…
Nov-26-24 04:01PM
Nov-12-24 11:01PM
Nov-11-24 05:00AM
Nov-07-24 04:01PM
Oct-22-24 04:01PM
Sep-19-24 04:01PM
Aug-20-24 04:01PM
Aug-14-24 04:01PM
Jul-30-24 04:01PM
Jun-20-24 04:01PM
09:47AM
08:26AM
07:28AM
May-15-24 11:27AM
May-13-24 09:53AM
10:50AM Loading…
Feb-27-24 10:50AM
Feb-01-24 02:25PM
Jan-31-24 10:40AM
06:42AM
Jan-30-24 02:52PM
02:38PM
08:00AM
Nov-08-23 09:40AM
Oct-23-23 09:40AM
Oct-06-23 09:40AM
Jul-13-23 07:08AM
Jul-12-23 07:00AM
Jun-12-23 07:00AM
May-22-23 07:00AM
May-18-23 02:53PM
07:00AM
May-11-23 07:00AM
May-01-23 07:30AM
Mar-23-23 07:00AM
Mar-03-23 07:00AM
Feb-09-23 07:00AM
Jan-05-23 07:00AM
Dec-07-22 07:30AM
Nov-17-22 07:00AM
Nov-08-22 07:00AM
Nov-07-22 07:00AM
Nov-03-22 07:00AM
Oct-27-22 07:00AM
Oct-25-22 07:00AM
Oct-18-22 07:00AM
Oct-11-22 07:00AM
Oct-06-22 07:00AM
Sep-27-22 07:00AM
Sep-20-22 07:00AM
Sep-14-22 07:28AM
Sep-08-22 07:00AM
Aug-31-22 07:00AM
Aug-09-22 07:00AM
Aug-04-22 07:00AM
Aug-01-22 07:00AM
Jul-13-22 07:00AM
Jul-06-22 07:00AM
May-18-22 03:12PM
12:41PM
07:00AM
May-17-22 12:15PM
07:00AM
May-16-22 07:00AM
May-10-22 07:00AM
May-06-22 07:00AM
May-03-22 07:00AM
Apr-06-22 12:36PM
07:00AM
Apr-05-22 12:54PM
07:00AM
Mar-17-22 07:00AM
Mar-01-22 07:00AM
Feb-21-22 12:14PM
Feb-09-22 12:55PM
07:00AM
Feb-04-22 07:00AM
Feb-03-22 10:00AM
Feb-01-22 07:00AM
Jan-28-22 07:00AM
Jan-27-22 07:00AM
Jan-25-22 10:00AM
Jan-07-22 10:00AM
Jan-06-22 07:00AM
Jan-04-22 02:28PM
09:07AM
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPRINGER TIMOTHY ADirectorApr 11 '25Buy16.3153,706875,9451,503,358Apr 11 06:12 PM
SPRINGER TIMOTHY ADirectorApr 10 '25Buy16.7345,858767,2041,449,652Apr 11 06:12 PM
SPRINGER TIMOTHY ADirectorApr 09 '25Buy14.7621,071311,0201,403,794Apr 11 06:12 PM
SPRINGER TIMOTHY ADirectorApr 11 '25Buy16.319,478154,5864,334,846Apr 11 06:12 PM
SPRINGER TIMOTHY ADirectorApr 10 '25Buy16.738,092135,3794,325,368Apr 11 06:12 PM
SPRINGER TIMOTHY ADirectorApr 09 '25Buy14.763,71854,8804,317,276Apr 11 06:12 PM
SPRINGER TIMOTHY ADirectorApr 07 '25Buy17.10412,5007,053,7501,382,723Apr 09 05:38 PM
SPRINGER TIMOTHY ADirectorApr 07 '25Buy17.1087,5001,496,2504,313,558Apr 09 05:38 PM
MCGUIRE TERRANCEDirectorApr 07 '25Sale17.10500,0008,550,000573,062Apr 07 05:02 PM
SPRINGER TIMOTHY ADirectorFeb 05 '25Buy50.00660,00033,000,000970,223Feb 07 04:21 PM
SPRINGER TIMOTHY ADirectorFeb 05 '25Buy54.14129,2946,999,9774,226,058Feb 07 04:21 PM
Lochner DanielChief Financial OfficerFeb 05 '25Buy54.144,617249,9644,617Feb 07 04:19 PM
Schwabish MarcChief Business OfficerJan 28 '25Option Exercise2.382,7006,4264,700Jan 29 04:05 PM
Schwabish MarcChief Business OfficerDec 09 '24Option Exercise2.382,0004,7602,000Dec 11 04:21 PM
McNamara PeterChief Scientific OfficerDec 03 '24Option Exercise2.383,5008,33014,188Dec 05 04:32 PM
SPRINGER TIMOTHY ADirectorOct 22 '24Buy33.59300,00010,077,0004,096,764Oct 24 05:04 PM
SPRINGER TIMOTHY ADirectorSep 26 '24Buy28.8250,0001,440,8293,796,764Sep 26 06:15 PM